PT  - JOURNAL ARTICLE
AU  - Shah, Anoop D.
AU  - Subramanian, Anuradhaa
AU  - Lewis, Jadene
AU  - Dhalla, Samir
AU  - Ford, Elizabeth
AU  - Haroon, Shamil
AU  - Kuan, Valerie
AU  - Nirantharakumar, Krishnarajah
TI  - Long Covid symptoms and diagnosis in primary care: a cohort study using structured and unstructured data in The Health Improvement Network primary care database
AID  - 10.1101/2023.01.06.23284202
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.01.06.23284202
4099  - http://medrxiv.org/content/early/2023/01/09/2023.01.06.23284202.short
4100  - http://medrxiv.org/content/early/2023/01/09/2023.01.06.23284202.full
AB  - BACKGROUND Long Covid is a widely recognised consequence of COVID-19 infection, but little is known about the burden of symptoms that patients present with in primary care, as these are typically recorded only in free text clinical notes. Our objectives were to compare symptoms in patients with and without a history of COVID-19, and investigate symptoms associated with a Long Covid diagnosis.METHODS We used primary care electronic health record data from The Health Improvement Network (THIN), a Cegedim database. We included adults registered with participating practices in England, Scotland or Wales. We extracted information about 89 symptoms and ‘Long Covid’ diagnoses from free text using natural language processing. We calculated hazard ratios (adjusted for age, sex, baseline medical conditions and prior symptoms) for each symptom from 12 weeks after the COVID-19 diagnosis.FINDINGS We compared 11,015 patients with confirmed COVID-19 and 18,098 unexposed controls. Only 20% of symptom records were coded, with 80% in free text. A wide range of symptoms were associated with COVID-19 at least 12 weeks post-infection, with strongest associations for fatigue (adjusted hazard ratio (aHR) 3.99, 95% confidence interval (CI) 3.59, 4.44), shortness of breath (aHR 3.14, 95% CI 2.88, 3.42), palpitations (aHR 2.75, 95% CI 2.28, 3.32), and phlegm (aHR 2.88, 95% CI 2.30, 3.61). However, a limited subset of symptoms were recorded within 7 days prior to a Long Covid diagnosis in more than 20% of cases: shortness of breath, chest pain, pain, fatigue, cough, and anxiety / depression.CONCLUSION Numerous symptoms are reported to primary care at least 12 weeks after COVID-19 infection, but only a subset are commonly associated with a GP diagnosis of Long Covid.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: ADS has received funding from THIS Institute, NIHR, UKRI and British Heart Foundation. VK has received funding from UKRI and NIHR. EF has received funding from NIHR. KN has received funding from NIHR, UKRI, MRC, Kennedy Trust for Rheumatology Research, Health Data Research UK, Wellcome Trust, European Regional Development Fund, Institute for Global Innovation, Boehringer Ingelheim, Action Against Macular Degeneration Charity, Midlands Neuroscience Teaching and Development Funds, South Asian Health Foundation, Vifor Pharma, College of Police, and CSL Behring. KN has received consulting fees from BI, Sanofi, CEGEDIM, MSD and holds a leadership / fiduciary role with NICST, a charity and OpenClinical, a Social Enterprise.Funding StatementThis work was supported by Health Data Research UK, which receives its funding from the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and the Wellcome Trust. This study was supported by the National Institute for Health Research (NIHR) CONVALESCENCE grant (COV-LT-0009). ADS is funded by a postdoctoral fellowship from THIS Institute, NIHR (AI_AWARD01864 and COV-LT-0009), UKRI (Horizon Europe Guarantee for DataTools4Heart) and British Heart Foundation Accelerator Award (AA/18/6/24223). VK is supported by the UKRI/NIHR Strategic Priorities Award in Multimorbidity Research (MR/V033867/1) for the Multimorbidity Mechanism and Therapeutics Research Collaborative. EF is supported by the NIHR Applied Research Collaboration Kent Surrey and Sussex (grant number NIHR200179). KN has been awarded research grants from NIHR, UKRI/MRC, Kennedy Trust for Rheumatology Research, Health Data Research UK, Wellcome Trust, European Regional Development Fund, Institute for Global Innovation, Boehringer Ingelheim, Action Against Macular Degeneration Charity, Midlands Neuroscience Teaching and Development Funds, South Asian Health Foundation, Vifor Pharma, College of Police, and CSL Behring, all payments were made to his academic institution; Krishnarajah Nirantharakumar received consulting fees from BI, Sanofi, CEGEDIM, MSD and holds a leadership/fiduciary role with NICST, a charity and OpenClinical, a Social Enterprise.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the North East - Tyne & Wear South Research Ethics Committee (20/NE/0209).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study uses individual patient data including free text from general practice records, and access to data is therefore restricted. Access to the structured data for research from the THIN database can be sought from The Health Improvement Network Ltd. (a Cegedim company). Applications need to be approved by the THIN Scientific Review Committee. Access to the free text was available for a limited time period for COVID-19 research under the NHS Digital Control of Patient Information (COPI) notice, and approval for further research will need to be sought from the Health Research Authority Confidentiality Advisory Group for a section 251 exemption. R codelists for symptom definitions are available from https://github.com/AnuSub/LongCOVID_Symptoms_CodeList.